

THOUGHT LEADERSHIP

NEWS RELEASES

PUBLISHED: AUGUST 26, 2021

**Service**Generic Drug / ANDA
Litigation**Industry**

Life Sciences

Professional

DON J. MIZERK

CHICAGO:

312.526.1546

DON.MIZERK@

HUSCHBLACKWELL.COM

Husch Blackwell Again Recognized by Patexia as a Top ANDA Litigation Law Firm

Husch Blackwell has again been recognized by Patexia, the world's largest network for intellectual property professionals, in its ANDA Litigation Intelligence Report 2021 as being a top law firm handling Abbreviated New Drug Application (ANDA) litigation.

Patexia's study measured the performance and activity of stakeholder organizations, including attorneys, law firms, pharmaceutical companies and judges, evaluating more than 240 law firms and 1,471 attorneys over a four-year period ending in June 2021. The study analyzed more than 1,100 cases involving over 1,200 patents.

Husch Blackwell was ranked among the top 25 firms for its performance on behalf of defendants in ANDA litigation. Partner Don Mizerk garnered individual rankings among the *most active* ANDA attorneys on the defendant side and among *best performing* attorneys representing defendants. Husch Blackwell's ANDA litigation team also placed among the top 50 of most active law firms representing generic drug makers as defendants in ANDA litigation, with eight cases appearing in the study.

Husch Blackwell's ANDA litigation team spans multiple offices and is composed of 16 lawyers and two scientific advisors. The team has handled litigation involving blockbuster drug categories, including anticoagulants, antidepressants, H₁ antagonists, and antiarrhythmic agents.